ChemoCentryx Inc (CCXI) - Financial Analysis Review

Summary

ChemoCentryx Inc (ChemoCentryx) discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders with major focus on orphan and rare diseases. Its pipeline products include C5aR programs, CCR2 program, CCR9 program, and CCR1 program. ChemoCentryxs C5aR Program is for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis. The companys CCR2 Program provides CCX140 for the treatment of diabetic nephropathy, a form of kidney disease and CCX872 for the treatment of pancreatic cancer.

GlobalData's ChemoCentryx Inc (CCXI) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

ChemoCentryx Inc Key Recent Developments:

Nov 07,2016: ChemoCentryx Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Oct 20,2016: ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors
Oct 17,2016: FDA awards 21 grants to stimulate product development for rare diseases
Aug 08,2016: ChemoCentryx Reports Second Quarter 2016 Financial Results and Provides Corporate Update
May 10,2016: ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.